PBH

Business Context and Reporting Period

Company: Prestige Consumer Healthcare Inc. (Prestige Brands Holdings, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2006
Business Overview: The Company markets and distributes well-recognized, brand-name over-the-counter (OTC) drugs, household cleaning, and personal care products. It operates in niche segments, utilizing a low-cost operating model that outsources manufacturing and logistics to third-party providers. The portfolio includes 13 major brands (e.g., Chloraseptic, Clear Eyes, Comet, Cutex) which accounted for approximately 93% of net sales in 2006.

Key Financial Metrics (Fiscal Year 2006)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 2.6% to $296.7 million, driven by the acquisitions of Dental Concepts (The Doctor's brand) and Chore Boy, as well as full-year revenue from the Little Remedies brand.
  • OTC Drug Segment: Sales up 1.2% to $160.9 million.
  • Household Cleaning Segment: Sales up 10.1% to $107.8 million.
  • Personal Care Segment: Sales declined 13.2% to $27.9 million due to competition in the dandruff shampoo category (Denorex) and softness in the nail polish remover category (Cutex).
• Profitability: Net income increased significantly to $26.3 million from $10.2 million in 2005. This improvement was aided by a reduction in interest expense ($36.3 million vs. $44.7 million) and the absence of the $26.9 million loss on debt extinguishment recorded in 2005.
• Impairment Charges: The Company recorded a non-cash impairment charge of $9.3 million ($7.4 million for intangible assets and $1.9 million for goodwill) in the Personal Care segment due to declining sales and fair value adjustments.

Guidance, Outlook, Risks, and Unusual Items

• Outlook & Strategy: Management plans to continue growth through advertising investment, new product introductions (e.g., Clear Eyes Triple Action Relief), and strategic acquisitions. International sales remain a small portion (approx. 3%) of net sales but are a focus for expansion.
• Unusual Items:
  • Impairment: $9.3 million non-cash charge in Q4 2006 related to Personal Care segment assets.
  • Legal Proceedings: The Company is a defendant in a consolidated securities class action lawsuit regarding its 2005 IPO and alleged failure to disclose declining demand. Management believes allegations are unfounded. Additionally, Similasan Corporation filed a lawsuit alleging trademark infringement regarding Murine homeopathic products.
• Risks:
  • Customer Concentration: Wal-Mart accounted for approximately 21% of gross sales in 2006. The top 10 customers accounted for 51% of sales.
  • Manufacturing Dependence: The Company relies entirely on third-party manufacturers. Approximately 34% of gross sales are produced by manufacturers with whom the Company has no long-term contracts.
  • Debt Covenants: The Company has substantial indebtedness ($498.6 million) and is subject to restrictive covenants regarding leverage and interest coverage ratios. Failure to comply could result in debt acceleration.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the relationship with Wal-Mart, which represents over 20% of sales.
• Personal Care Segment Turnaround: Assess the effectiveness of management's strategy to reverse the 13.2% sales decline in the Personal Care segment, which triggered significant impairment charges.
• Debt Service Capacity: Confirm the Company's ability to maintain required leverage and interest coverage ratios given the $498.6 million debt load and $36.3 million annual interest expense.
• Legal Exposure: Monitor the status of the securities class action lawsuit and the Similasan trademark dispute for potential financial impact.
• Supply Chain Resilience: Evaluate the risk associated with the lack of long-term contracts for 34% of manufacturing output.